Advertisement
IXJ vs XLV
Which ETF would AI Choose? iShares Global Healthcare ETF (IXJ) vs. Health Care Select Sector SPDR Fund (XLV)
Key Takeaways
- IXJ provides global healthcare exposure tracking the S&P Global 1200 Health Care (Sector) Capped Index, while XLV offers concentrated U.S. large-cap healthcare exposure via the Health Care Select Sector Index.
- IXJ holds approximately 110 securities with meaningful allocations to international firms such as Roche and Novartis; XLV maintains a tighter portfolio of roughly 60 holdings drawn exclusively from the S&P 500.
- Expense ratios differ materially: IXJ charges 0.38 percent annually, whereas XLV charges 0.08 percent, giving the latter a clear cost advantage for long-term investors.
- Both ETFs are passively managed, market-capitalization-weighted vehicles focused on pharmaceuticals, biotechnology, and healthcare equipment and services, yet IXJ adds geographic diversification while XLV emphasizes liquidity and lower volatility within U.S. mega-caps.
- Top holdings overlap significantly (Eli Lilly, Johnson & Johnson, AbbVie), but XLV assigns heavier weights to these names, resulting in greater concentration risk compared with IXJ’s broader global footprint.
- In recent market cycles, sector rotation driven by innovation in weight-loss therapies and aging demographics has supported both funds, with XLV benefiting from superior cost efficiency and domestic liquidity during periods of U.S. equity outperformance.
Introduction
Healthcare remains a defensive growth sector supported by long-term demographic trends and pharmaceutical innovation. Investors seeking targeted exposure frequently compare iShares Global Healthcare ETF (IXJ) and Health Care Select Sector SPDR Fund (XLV). The two funds do not compete directly; instead, they deliver alternative implementations of healthcare sector exposure. IXJ emphasizes global diversification, while XLV provides efficient access to the largest U.S. healthcare companies. Understanding their structural differences helps investors align allocations with risk tolerance, geographic preferences, and cost sensitivity in the current environment of elevated interest rates and evolving regulatory scrutiny.
iShares Global Healthcare ETF (IXJ) Overview
IXJ seeks to track the S&P Global 1200 Health Care (Sector) Capped Index (Net). The fund employs full replication and holds approximately 110 securities. Geographic allocation typically features 70–75 percent in the United States, with the balance in Switzerland, the United Kingdom, and other developed markets. Sector weights concentrate in pharmaceuticals, biotechnology, and life sciences (roughly 70 percent) and healthcare equipment and services (approximately 29 percent). The expense ratio stands at 0.38 percent. Top holdings include Eli Lilly (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), UnitedHealth Group (UNH), and Merck (MRK), supplemented by international names such as Roche and Novartis. The ETF is passively managed with semi-annual distributions and exhibits moderate liquidity suitable for most investors.
Health Care Select Sector SPDR Fund (XLV) Overview
XLV tracks the Health Care Select Sector Index, representing the healthcare component of the S&P 500. It also uses full replication and typically holds 60–64 securities. All holdings are U.S.-listed companies, with nearly 100 percent domestic exposure. The same sub-sectors dominate: pharmaceuticals, biotechnology, and healthcare equipment and services. The expense ratio is 0.08 percent, among the lowest in the category. Top holdings mirror IXJ but with higher concentration—Eli Lilly often exceeds 15 percent, followed by Johnson & Johnson, AbbVie, UnitedHealth Group, and Merck. XLV is passively managed with quarterly distributions and maintains exceptional liquidity, frequently ranking among the most actively traded sector ETFs.
Industry and Thematic Backdrop
The healthcare sector continues to benefit from structural tailwinds including aging populations in developed economies, advances in GLP-1 weight-loss therapies, and ongoing biotechnology innovation. Capital flows have favored large-cap pharmaceutical and device makers amid favorable clinical pipelines. Regulatory developments, including potential drug-pricing reforms and patent-cliff risks, introduce periodic volatility. Macroeconomic drivers such as interest-rate expectations influence valuation multiples, while geopolitical tensions have limited direct impact on the largely domestic U.S. and European healthcare supply chains. Both ETFs remain positioned to capture these durable trends without leverage or active thematic overlays.
Performance and Positioning Comparison
Over recent weeks and months, both ETFs have reflected sector rotation toward innovative therapies and defensive healthcare spending. XLV’s heavier weighting in top U.S. names has produced modestly higher volatility during earnings seasons but also captured outsized gains when mega-cap pharmaceutical stocks rallied. IXJ’s international exposure has provided a modest cushion during periods of U.S. dollar strength or relative underperformance abroad. In broader market cycles, XLV’s lower expense ratio and superior liquidity have enhanced compounding for buy-and-hold investors, while IXJ has offered smoother returns through geographic diversification. Relative positioning favors XLV for cost-conscious, U.S.-centric portfolios and IXJ for investors seeking broader global healthcare representation.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening.
Tickeron AI Verdict
Based on observable factors including structural strength, cost efficiency, diversification profile, trend consistency, sector momentum, and risk exposure, Tickeron’s AI would currently assign a modest probabilistic preference to XLV. Its significantly lower expense ratio, exceptional liquidity, and concentrated exposure to leading U.S. healthcare innovators align with prevailing sector momentum and cost-sensitive positioning, although IXJ remains a viable alternative for investors prioritizing global diversification.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsTo compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IXJ is a StrongBuy and XLV is a StrongBuy.
IXJ in upward trend: 10-day moving average broke above 50-day moving average on October 19, 2026
The 10-day moving average for IXJ crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on IXJ as a result. In 72 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for IXJ just turned positive on October 12, 2026. Looking at past instances where IXJ's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
IXJ moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where IXJ advanced for three days, in 260 of 324 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for IXJ moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 30 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IXJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
IXJ broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IXJ entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
XLV in upward trend: 10-day moving average crossed above 50-day moving average on October 15, 2026
The 10-day moving average for XLV crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on XLV as a result. In 77 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for XLV just turned positive on October 09, 2026. Looking at past instances where XLV's MACD turned positive, the stock continued to rise in 43 of 48 cases over the following month. The odds of a continued upward trend are 90%.
XLV moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in 265 of 327 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 222 of 271 cases where XLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for XLV moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 30 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
XLV broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
| IXJ | XLV | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 83% | 4 days ago 81% |
| Stochastic ODDS (%) | 4 days ago 72% | 4 days ago 77% |
| Momentum ODDS (%) | 4 days ago 78% | 4 days ago 79% |
| MACD ODDS (%) | 4 days ago 84% | 4 days ago 90% |
| TrendWeek ODDS (%) | 4 days ago 79% | 4 days ago 82% |
| TrendMonth ODDS (%) | 4 days ago 80% | 4 days ago 84% |
| Advances ODDS (%) | 12 days ago 80% | 12 days ago 81% |
| Declines ODDS (%) | 8 days ago 77% | 8 days ago 82% |
| BollingerBands ODDS (%) | 4 days ago 79% | 4 days ago 80% |
| Aroon ODDS (%) | 4 days ago 89% | 4 days ago 82% |
Advertisement
IXJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, IXJ has been closely correlated with LLY. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if IXJ jumps, then LLY could also see price increases.
XLV and
Correlation & Price change
A.I.dvisor indicates that over the last year, XLV has been closely correlated with LLY. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if XLV jumps, then LLY could also see price increases.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ETG | 22.88 | N/A | N/A |
| Eaton Vance Tax-Advantaged Global Dividend Income Fund | |||
| GDL | 8.29 | -0.01 | -0.12% |
| GDL Fund (The) | |||
| HPI | 13.21 | -0.09 | -0.68% |
| John Hancock Preferred Income Fund | |||
| RETL | 8.47 | -0.44 | -4.94% |
| Direxion Daily Retail Bull 3X ETF (RETL) | |||
| ASTN | 34.07 | -1.80 | -5.02% |
| Defiance Daily Target 2X Short ASTS ETF (ASTN) | |||